Shares of Tempus AI (TEM), a leading precision medicine and AI technology company, plummeted 11.91% intraday on Monday, following the company's announcement of preliminary, unaudited financial results for the fourth quarter and full year 2024.
While Tempus AI reported an expected revenue growth of around 30% year-over-year to approximately $693 million for the full year 2024 and a 35% increase in Q4 2024 revenue to around $200 million, the company acknowledged softness in its contract research organization (CRO) revenues.
"Despite some softness in our CRO revenues, our core businesses gained momentum throughout the year," said Eric Lefkofsky, Tempus' Founder and CEO, in a statement. This admission of weakness in the CRO segment, which provides research services to pharmaceutical and biotechnology companies, likely contributed to the stock's sharp decline despite the overall revenue growth and continued improvement in adjusted EBITDA.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。